Chapter 33. Acute Myeloid Leukemia in Adults: Remission Induction Therapy

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Cara A. Rosenbaum MD and
  2. Richard A. Larson MD

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch33

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Rosenbaum, C. A. and Larson, R. A. (2009) Acute Myeloid Leukemia in Adults: Remission Induction Therapy, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch33

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Section of Hematology/Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • acute myeloid leukemia (AML);
  • acute myeloid leukemia - remission;
  • remission induction regimens and best outcomes;
  • cytogenetic/molecular subsets in acute myeloid leukemia and treatment outcomes;
  • cytarabine dose;
  • optimum anthracycline agent and dose;
  • role of multiple courses of induction therapy;
  • SWOG/CALGB intergroup trial

Summary

This chapter contains sections titled:

  • Introduction

  • Literature-search strategy and inclusions

  • Which remission induction regimens give the best outcomes?

  • What is the optimum anthracycline agent and dose?

  • What is the role of cytarabine dose?

  • What is the role of adding other agents to 7 + 3?

  • What is the role of multiple courses of induction therapy?

  • What is the role of myeloid growth factors in the initial treatment of AML?

  • References